MIRA PHARMACEUTICALS, INC.
MIRA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MIRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MIRA
MIRA Pharmaceuticals, Inc. is a preclinical-stage biopharmaceutical company developing novel small-molecule therapies for neurological and metabolic disorders, with lead candidate Ketamir-2 advancing toward Phase 2a in chemotherapy-induced peripheral neuropathy.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials for MIRA PHARMACEUTICALS, INC..
Similar companies
MIRA Pharmaceuticals, Inc. is a preclinical-stage biopharmaceutical company developing novel small-molecule therapies for neurological and metabolic disorders, with lead candidate Ketamir-2 advancing toward Phase 2a in chemotherapy-induced peripheral neuropathy.
- Lead candidate Ketamir-2, an oral NMDA receptor modulator, completed Phase 1 dosing with no serious adverse events or dose-limiting toxicities reported; Phase 2a in CIPN targeted for Q1 2027 [sec_mda · as of 2026-08-12].
- Preclinical pipeline includes SKNY-1 for weight loss/nicotine addiction and MIRA-55 for inflammatory pain; both are oral small-molecule programs [sec · filed 2026-02-02].
- Cash and equivalents were $3.6M as of June 30, 2025 [sec]; net loss for the six months ended June 30, 2025 was $1.2M [sec].
- The company plans to monetize product candidates after Phase II studies but may require additional capital before then [sec_mda · as of 2026-08-12].
- SKNY-1 demonstrated dose-dependent weight reduction and lipid normalization in preclinical studies, with a differentiated CNS safety profile [sec_mda · as of 2026-08-12].
What works
- Ketamir-2 Phase 1 data showed no serious adverse events or dose-limiting toxicities, supporting advancement to Phase 2a [sec_mda · as of 2026-08-12].
- SKNY-1 preclinical data showed dose-dependent weight loss and reduced hepatic triglycerides, with a safety profile avoiding anxiety-related effects [sec_mda · as of 2026-08-12].
- The DEA concluded that Ketamir-2 and MIRA-55 are not controlled substances, potentially simplifying regulatory pathways [sec_mda · as of 2025-05-14].
What to weigh
- Cash of $3.6M as of June 30, 2025 is limited; the company acknowledges additional capital may be required before Phase II monetization [sec_mda · as of 2026-08-12].
- The company has no approved products and is in early-stage development, with all candidates in preclinical or Phase 1 stages [sec_mda · as of 2026-08-12].
- If additional funding is not obtained on acceptable terms, the company may need to delay or scale back operations, potentially diluting existing shareholders [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Ketamir-2 Phase 1 completed with no serious adverse events
“Based on preliminary safety data reviewed to date, no serious adverse events or dose-limiting toxicities have been reported”
SEC MD&A · August 12, 2026
SKNY-1 preclinical efficacy in weight loss
“oral SKNY-1 demonstrated dose-dependent reductions in body weight, lipid normalization, and reduced hepatic triglyceride accumulation”
SEC MD&A · August 12, 2026
DEA classification of Ketamir-2 and MIRA-55
“The DEA's scientific review of Ketamir-2 and MIRA-55 concluded that it would not be considered a controlled substance or listed chemical under the CSA”
SEC MD&A · May 14, 2025
Risks & what to watch (3)›
Key risks
- Limited cash runway — Cash of $3.6M as of June 30, 2025 may be insufficient to complete planned development without additional funding [sec].
- Early-stage pipeline — All candidates are preclinical or Phase 1; no approved products or revenue [sec_mda · as of 2026-08-12].
- Dependence on external capital — Company may need to raise funds through equity or debt, causing dilution or unfavorable terms [sec_mda · as of 2026-08-12].
What to watch
- Initiation of Phase 2a trial for Ketamir-2 in CIPN, targeted for Q1 2027 [sec_mda · as of 2026-08-12].
- Presentation of Phase 1 data on Ketamir-2 at AACR Annual Meeting in April 2026 [sec · filed 2026-02-02].
- Progress of SKNY-1 CMC activities and IND-enabling studies [sec_mda · as of 2026-08-12].
- Any partnering discussions or financing events to extend cash runway [sec · filed 2026-02-02].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run MIRA PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MIRA PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
19.7 months
D/E 0.01
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
25
Total value held
$2.9M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,387,824 | $1.5M |
| cross staff investments inc | 359,401 | $385K |
| geode capital management, llc | 290,890 | $311K |
| vanguard fiduciary trust co | 169,483 | $181K |
| blackrock, inc. | 112,346 | $120K |
| northern trust corp | 67,698 | $72K |
| first american bank | 60,000 | $64K |
| state street corp | 49,100 | $53K |
| xtx topco ltd | 37,573 | $40K |
| commonwealth equity services, llc | 35,067 | $38K |
Showing top 10 of 25 institutional holders of MIRA PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 1.1%
- Days to cover
- 2.5
- Shares short
- 437,032
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MIRA short interestGovernance
Frequently asked questions
What is the AI investment thesis for MIRA PHARMACEUTICALS, INC.?
MIRA Pharmaceuticals, Inc. is a preclinical-stage biopharmaceutical company developing novel small-molecule therapies for neurological and metabolic disorders, with lead candidate Ketamir-2 advancing toward Phase 2a in chemotherapy-induced peripheral neuropathy.
What is MIRA PHARMACEUTICALS, INC.'s lead drug candidate?
MIRA PHARMACEUTICALS, INC.'s most advanced tracked candidate is ketamir-2 (Phase 1) for Healthy Adult Participants.
Who is the CEO of MIRA PHARMACEUTICALS, INC.?
Mr. Erez Aminov is the chief executive officer of MIRA PHARMACEUTICALS, INC. (MIRA).
Where is MIRA PHARMACEUTICALS, INC. headquartered?
MIRA PHARMACEUTICALS, INC. (MIRA) is headquartered in Miami, FL, United States.
What therapeutic areas does MIRA PHARMACEUTICALS, INC. focus on?
MIRA PHARMACEUTICALS, INC. develops therapies across Metabolic, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.